- Current report filing (8-K)
June 04 2012 - 1:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): June 4,
2012
CHINA BIOLOGIC PRODUCTS, INC.
|
(Exact name of registrant as specified in
its charter)
|
|
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
18th Floor, Jialong International Building
19 Chaoyang
Park Road
Chaoyang District, Beijing 100125
Peoples Republic of
China
(Address of Principal Executive Offices)
86 10 6598 3111
Registrant's telephone number,
including area code
____________________________________________________________
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 7.01 REGULATION FD DISCLOSURE.
On June 4, 2012, China Biologic Products, Inc. (the Company)
issued a press release announcing its plan to attend the Jefferies 2012 Global
Healthcare Conference (the Conference) in New York, NY on June 7, 2012. Copy
of the press release and the presentation materials that the Company plans to
use during the Conference, which the Company is furnishing to the Securities and
Exchange Commission, are attached hereto as Exhibit 99.1 and Exhibit 99.2,
respectively, and incorporated by reference herein.
The information contained in this Current Report on Form 8-K
and the exhibits attached hereto shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section, nor shall such
information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing. The
disclosure in this Current Report on Form 8-K, including the exhibits attached
hereto, of any information (financial or otherwise) does not constitute an
admission that such information is material.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 4, 2012
CHINA BIOLOGIC PRODUCTS, INC.
By:
/s/ David (Xiaoying) Gao
David (Xiaoying) Gao
Chief Executive Officer
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024